← Eichor
Study identifier: NCT07234591 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis

Condition: Plaque Psoriasis · Moderate to Severe Plaque Psoriasis  ·  Sponsor: Usynova Pharmaceuticals Ltd.

PhaseNA
Planned participants140
Who can joinAll sexes, 18 Years to 70 Years
Healthy volunteersNo

About this study

A Study to evaluate efficacy and safety in subjects with moderate to severe Plaque Psoriasis treated with a TYK2 Inhibitor for 12 weeks

This description comes directly from the study's public registry record.

Talk to the study team

Yang Zhang  ·  +8613636393195  ·  yang_zhang@usynova.com

Always discuss trial participation with your own doctor first.

Locations (1)

Shanghai Skin Disease HospitalShanghai, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07234591